6 Biotechnology Stocks to Buy Now

Advertisement

Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

NPS Pharmaceuticals, Inc. (NPSP) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. In Portfolio Grader’s specific subcategory of Sales Growth, NPSP also gets an A. For more information, get Portfolio Grader’s complete analysis of NPSP stock.

Foundation Medicine, Inc. (FMI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of FMI stock.

This week, MediciNova, Inc. (MNOV) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

United Therapeutics Corporation (UTHR) gets a higher grade this week, advancing from a C last week to a B. United Therapeutics is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

This week, ZIOPHARM Oncology, Inc.’s (ZIOP) ratings are up from a C last week to a B. ZIOPHARM Oncology is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

This is a strong week for Ambit Biosciences Corp. (AMBI). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/6-biotechnology-stocks-to-buy-now-npsp-fmi-mnov/.

©2024 InvestorPlace Media, LLC